Nuvectis Pharma, Inc. Increase (Decrease) in Accrued Liabilities
Nuvectis Pharma, Inc. (NVCT) reported Increase (Decrease) in Accrued Liabilities of -$23.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-04
- Nuvectis Pharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $56.00K.
- Nuvectis Pharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$79.00K, a 416.00% decline year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $50.00K, a 91.04% decline year-over-year.
- Nuvectis Pharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $63.00K.
- Nuvectis Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$725.00K, a 270.59% decline from fiscal 2024.
- Nuvectis Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $425.00K.
- Nuvectis Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$30.00K, a 108.88% decline from fiscal 2022.
- Nuvectis Pharma, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $338.00K.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $56.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$23.00K 10-Q · filed 2026-08-04 | $27.00K derived: sum of 3 quarters · filed 2026-08-04 | $90.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$79.00K 10-Q · filed 2026-05-05 | -$29.00K derived: sum of 2 quarters · filed 2026-05-05 | $34.00K derived: sum of 3 quarters · filed 2026-05-05 | -$829.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $113.00K derived: sum of 2 quarters · filed 2026-02-11 | -$750.00K derived: sum of 3 quarters · filed 2026-08-04 | -$725.00K 10-K · filed 2026-02-11 |
| 2025-09-30 | $63.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$800.00K derived: sum of 2 quarters · filed 2026-08-04 | -$775.00K 10-Q · filed 2025-11-04 | -$217.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$863.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$838.00K 10-Q · filed 2026-08-04 | -$280.00K derived: sum of 3 quarters · filed 2026-08-04 | -$308.00K derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $25.00K 10-Q · filed 2026-05-05 | $583.00K derived: sum of 2 quarters · filed 2026-05-05 | $555.00K derived: sum of 3 quarters · filed 2026-05-05 | $379.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $558.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $530.00K derived: sum of 2 quarters · filed 2026-02-11 | $354.00K derived: sum of 3 quarters · filed 2026-02-11 | $425.00K 10-K · filed 2026-02-11 |
| 2024-09-30 | -$28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$204.00K derived: sum of 2 quarters · filed 2025-11-04 | -$133.00K 10-Q · filed 2025-11-04 | $124.00K derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | -$176.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$105.00K 10-Q · filed 2025-08-05 | $152.00K derived: sum of 3 quarters · filed 2025-08-05 | -$261.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $71.00K 10-Q · filed 2025-05-06 | $328.00K derived: sum of 2 quarters · filed 2025-05-06 | -$85.00K derived: sum of 3 quarters · filed 2025-05-06 | $330.00K derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $257.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$156.00K derived: sum of 2 quarters · filed 2025-02-25 | $259.00K derived: sum of 3 quarters · filed 2025-02-25 | -$30.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | -$413.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $2.00K derived: sum of 2 quarters · filed 2024-11-05 | -$287.00K 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $415.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $126.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$289.00K 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $338.00K 10-K · filed 2024-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |